ReviewNature materials2026
Nanotechnology-mediated precision delivery of mRNA.
Review in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA-based therapeutics have been successful in preventing and treating various diseases. Nonetheless, these therapies still face difficulties in achieving specific delivery to organs, tissues and cells, which are exacerbated by the need to overcome multilevel biological barriers and intrinsically complex physiological disease characteristics. Several approaches are being developed to overcome these challenges, including optimizing administration routes, enhancing targeting abilities and facilitating responsive release. These tailored design strategies have been utilized in applications including mRNA vaccines, protein replacement and gene editing for enhanced precision therapies. This Review discusses various heterogeneous barriers for mRNA delivery and nanocarrier-mediated mRNA precision-delivery strategies, and highlights their uses in biomedical applications. Moreover, we discuss current limitations and future perspectives to accelerate the development of precision mRNA delivery to address current clinical needs.
Identifiers
42315665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.